Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension?

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

(2020) Fei Zhou et al.   LANCET

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China

(2020) Chaomin Wu et al.   JAMA Internal Medicine

Hypertension Hot Potato — Anatomy of the Angiotensin-Receptor Blocker Recalls

(2019) J. Brian Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

(2018) Paul K. Whelton et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

(2017) Clyde W. Yancy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

(2016) Piotr Ponikowski et al.   EUROPEAN HEART JOURNAL

Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials

(2016) Sripal Bangalore et al.   MAYO CLINIC PROCEEDINGS

Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus

(2016) Hongjing Gu et al.   Scientific Reports

Effects of blood pressure lowering on outcome incidence in hypertension

(2015) Costas Thomopoulos et al.   JOURNAL OF HYPERTENSION

Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality, Cardiovascular Deaths, and Cardiovascular Events in Patients With Diabetes Mellitus

(2014) Jun Cheng et al.   JAMA Internal Medicine

The Fixed-Dose Combination of Olmesartan/Amlodipine Was Superior in Central Aortic Blood Pressure Reduction Compared with Perindopril/Amlodipine: A Randomized, Double-Blind Trial in Patients with Hypertension

(2013) Luis Ruilope et al.   ADVANCES IN THERAPY

Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension

(2013) David B. Matchar et al.   ANNALS OF INTERNAL MEDICINE

Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril

(2013) G Bönner et al.   JOURNAL OF HUMAN HYPERTENSION

Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis

(2013) Nancy J. Brown   Nature Reviews Nephrology

Meta-Analysis of Randomized Trials of Angioedema as an Adverse Event of Renin–Angiotensin System Inhibitors

(2012) Harikrishna Makani et al.   AMERICAN JOURNAL OF CARDIOLOGY

Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients

(2012) Stefano Omboni et al.   JOURNAL OF HYPERTENSION

A Meta-Analysis Reporting Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients Without Heart Failure

(2012) Gianluigi Savarese et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats

(2008) I. Hamming et al.   EXPERIMENTAL PHYSIOLOGY

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

(2008) Johannes FE Mann et al.   LANCET

Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events

(2008)   NEW ENGLAND JOURNAL OF MEDICINE